Piper Sandler Reiterates Buy Rating on Abbott Laboratories
Piper Sandler reaffirms its buy rating on Abbott Laboratories with a $115 target price, a 25.85% upside from the current price.
Key Points
- Piper Sandler reiterated its buy rating on Abbott Laboratories with a price target of $115 on June 22, 2026.
- Piper Sandler's $115 price target implies 25.85% upside from Abbott Laboratories's ($ABT) current $91.38 share price.
- Abbott Laboratories' stock traded at $88.41 on Monday, with a market cap of $153.99 billion and a P/E ratio of 24.76.
- Insider buying activity at Abbott Laboratories included purchases by executives and directors in April and May 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Piper Sandler has reiterated its buy rating on Abbott Laboratories (NYSE: ABT) with a price target of $115. This reaffirmation came from analyst Adam Maeder on June 22, 2026. Abbott's shares traded at $88.41 on Monday.
Piper Sandler vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Abbott Laboratories
Several major institutional investors have adjusted their positions in Abbott Laboratories recently. BlackRock, Inc. trimmed its holdings by 1,221,310 shares, leaving it with 145,687,458 shares valued at approximately $14.96 billion, representing a 0.8% decrease. Vanguard Capital Management LLC opened a new position with 112,949,933 shares, worth about $11.60 billion. State Street Corp reduced its stake by 278,314 shares, now holding 79,575,468 shares valued at $8.17 billion, a 0.3% decrease. Capital Research Global Investors increased its position by 10,606,123 shares to 49,775,362 shares, valued at $5.11 billion, marking a 27.1% increase. Charles Schwab Investment Management Inc. significantly boosted its holdings by 32,310,527 shares, ending with 45,500,055 shares worth approximately $4.67 billion, a 245% increase.
Abbott Laboratories Stock Down 18.8%
Shares of Abbott Laboratories traded at $88.41 on Monday. The company boasts a market capitalization of $153.99 billion and a P/E ratio of 24.76, with a forward P/E of 14.59. Abbott's stock has a 52-week low of $81.97 and a high of $139.06. The 50-day moving average is $90.13, while the 200-day moving average stands at $113.64. Abbott maintains a current ratio of 1.39 and a quick ratio of 0.84, with a debt-to-equity ratio of 64.77.
$ABT price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Abbott Laboratories reported revenue of $45.13 billion, reflecting a 7.8% growth. The company achieved an EPS of $3.57, with a net margin of 13.9% and a return on equity of 12.3%. Abbott is scheduled to announce its next earnings results on July 16, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
8 target cuts vs 0 raises.
-
EPS & revenue
EPS met estimates. Revenue beat estimates by 0.5%.
-
Profit surprise
EBITDA missed by 43 percent. Operating income missed by 19 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
8 target cuts.
-
Earnings quality
Gross margin up 3.7 points. Positive free cash flow.
Earnings Call Summary
Abbott completed its $2.4 billion acquisition of Exact Sciences on March 23 and is integrating the cancer diagnostics business into its portfolio. First quarter results came in slightly ahead, with sales of $11.2 billion, up 3.7 percent on a comparable basis, though the respiratory season was weaker than expected. The company is seeing early signs of volume recovery in Nutrition after price increases, expects Core Lab Diagnostics to accelerate, and is launching new cardiac devices like the Volt pulsed field ablation catheter and TactiFlex Duo. Management remains confident in second half acceleration but is being cautious on near term market conditions.
Guidance Abbott cut full year earnings guidance from $5.68 to $5.48 per share, reflecting $0.20 of dilution from the Exact Sciences acquisition. The company guided full year revenue growth of 6.5 percent to 7.5 percent on a comparable basis including Exact Sciences. For the second quarter, Abbott expects earnings of $1.25 to $1.31 per share. Management said they are being conservative on respiratory season assumptions and expect acceleration in the second half driven by Nutrition recovery, Core Lab Diagnostics growth, and Exact Sciences integration.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Dividend
Abbott Laboratories offers an annual dividend rate of $2.52, yielding 2.85%. The dividend payout ratio is 67.23%.
Insider Buying and Selling at Abbott Laboratories
Recent insider activity at Abbott Laboratories includes several purchases. John Stratton bought 2,000 shares at an average price of $86.82 on May 7, 2026. Executive Vice President Mary Moreland acquired 5,314 shares at $94.41 on April 28, 2026. Daniel Starks purchased 10,000 shares at $92.65 on April 27, 2026. Additionally, Nita Ahuja, Daniel Starks, and Sally Blount each bought 2,286 shares on April 24, 2026.
Analysts Set New Price Targets
On June 22, 2026, Piper Sandler reiterated its buy rating on Abbott Laboratories with a $115 price target. Barclays also maintained a buy rating with a $143 target on April 20, 2026. The consensus among 24 analysts is a buy rating, with a mean price target of $116.54.
About Abbott Laboratories
Abbott Laboratories, headquartered in Abbott Park, Illinois, is a global healthcare company that develops and sells a wide range of medical devices, diagnostics, and nutritional products. The company operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Abbott employs approximately 122,000 people and is led by CEO Mr. Philip P. Boudreau.
Bottom Line
Piper Sandler's reiteration of its buy rating on Abbott Laboratories reflects continued confidence in the company's prospects. Abbott's diverse product line and strong market position make it a key player in the healthcare sector. As always, remember that 13F filings and analyst ratings are backward-looking and may not reflect current conditions.
Get Abbott Laboratories alerts
New 13F filings, insider trades, and analyst moves on $ABT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.